Table 3.
Risk Factor Associations with CaP by Baldness Pattern in AA Men – adjusted for age
| Age Group | Variables of Interest | No Baldness at age 30 | Any Baldness at age 30 | ||
|---|---|---|---|---|---|
| N | OR (95% CI) | N | OR (95% CI) | ||
| All ages | CaP Family history | 430 | 1.74 (1.14–2.67)a | 87 | 1.26 (0.48–3.35) |
| Alcohol (any weekly intake) | 426 | 1.42 (0.94–2.13) | 78 | 1.52 (0.56–4.09) | |
| Ever Smokers | 439 | 0.80 (0.53–1.21) | 93 | 0.80 (0.32–1.99) | |
| AR-CAG (≤21 repeats) | 193 | 1.42 (0.77–2.62) | 45 | 2.31 (0.41–12.93) | |
| SRD5A2 A49T (any T) | 165 | 1.34 (0.13–13.43) | 36 | --- | |
| SRD5A2 V89L (any L) | 187 | 1.09 (0.58–2.04) | 41 | 0.83 (0.16–4.30) | |
| CYP3A43 (*3) | 163 | 0.32 (0.15–0.70)a | 36 | 0.38 (0.04–3.97) | |
| CYP3A4 (any *1B) | 126 | 0.44 (0.17–1.20) | 28 | 0.17 (0.02–1.70) | |
| CYP3A5 (any *1) | 136 | 0.64 (0.26–1.58) | 31 | 2.52 (0.33–19.02) | |
| < Age 60 years | CaP Family history | 226 | 2.04 (1.14–3.65)a | 43 | 1.26 (0.32–4.97) |
| Alcohol (any weekly intake) | 223 | 1.56 (0.88–2.76) | 39 | 1.06 (0.27–4.14) | |
| Ever Smokers | 230 | 0.37 (0.20–0.69) a | 46 | 2.51 (0.66–9.57) | |
| AR-CAG (≤21 repeats) | 91 | 1.14 (0.46–2.82) | 22 | 1.45 (0.10–22.02) | |
| SRD5A2 A49T (any T) | --- | --- | --- | --- | |
| SRD5A2 V89L (any L) | 94 | 1.79 (0.70–4.58) | 19 | 0.17 (0.01–4.25) | |
| CYP3A43 (*3) | 80 | 0.21 (0.07–0.63)a | --- | --- | |
| CYP3A4 (any *1B) | 74 | 0.56 (0.18–1.78) | 12 | 0.95 (0.05–17.36) | |
| CYP3A5 (any *1) | 80 | 0.57 (0.19–1.70) | 13 | 2.39(0.14–39.95) | |
| ≥ Age 60 years | CaP Family history | 204 | 1.36 (0.68–2.73) | 44 | 2.82 (0.46–17.31) |
| Alcohol (any weekly intake) | 203 | 1.05 (0.56–1.99) | 39 | 2.08 (0.35–12.25) | |
| Ever Smokers | 209 | 1.30 (0.68–2.49) | 47 | 0.12 (0.02–0.80) | |
| AR-CAG (≤21 repeats) | 102 | 2.34 (0.92–5.96) | 23 | 3.04 (0.21–43.42) | |
| SRD5A2 A49T (any T) | --- | --- | --- | --- | |
| SRD5A2 V89L (any L) | 93 | 0.72 (0.27–1.88) | 22 | 1.39 (0.11–16.84) | |
| CYP3A43 (*3) | 83 | 0.65 (0.20–2.09) | 20 | 0.54 (0.04–6.54) | |
| CYP3A4 (any *1B) | 52 | 0.11 (0.01–1.40) | --- | --- | |
| CYP3A5 (any *1) | 56 | 0.87 (0.11–6.70) | 18 | 2.37 (0.10–55.07) | |
Significance levels:
a
=adjusted p ≤0.05 controlling the false discovery rate
Tests of heterogeneity of estimates showed no significant differences by baldness group.